CDK8-Novel Therapeutic Opportunities
Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/12/2/92 |
| id |
doaj-c4cd5f32f0144b26b6958c9304883c5a |
|---|---|
| record_format |
Article |
| spelling |
doaj-c4cd5f32f0144b26b6958c9304883c5a2020-11-25T02:36:41ZengMDPI AGPharmaceuticals1424-82472019-06-011229210.3390/ph12020092ph12020092CDK8-Novel Therapeutic OpportunitiesIngeborg Menzl0Agnieszka Witalisz-Siepracka1Veronika Sexl2Institute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, AustriaInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, AustriaInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, AustriaImprovements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.https://www.mdpi.com/1424-8247/12/2/92CDK8mediator complexcancer |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ingeborg Menzl Agnieszka Witalisz-Siepracka Veronika Sexl |
| spellingShingle |
Ingeborg Menzl Agnieszka Witalisz-Siepracka Veronika Sexl CDK8-Novel Therapeutic Opportunities Pharmaceuticals CDK8 mediator complex cancer |
| author_facet |
Ingeborg Menzl Agnieszka Witalisz-Siepracka Veronika Sexl |
| author_sort |
Ingeborg Menzl |
| title |
CDK8-Novel Therapeutic Opportunities |
| title_short |
CDK8-Novel Therapeutic Opportunities |
| title_full |
CDK8-Novel Therapeutic Opportunities |
| title_fullStr |
CDK8-Novel Therapeutic Opportunities |
| title_full_unstemmed |
CDK8-Novel Therapeutic Opportunities |
| title_sort |
cdk8-novel therapeutic opportunities |
| publisher |
MDPI AG |
| series |
Pharmaceuticals |
| issn |
1424-8247 |
| publishDate |
2019-06-01 |
| description |
Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues. |
| topic |
CDK8 mediator complex cancer |
| url |
https://www.mdpi.com/1424-8247/12/2/92 |
| work_keys_str_mv |
AT ingeborgmenzl cdk8noveltherapeuticopportunities AT agnieszkawitaliszsiepracka cdk8noveltherapeuticopportunities AT veronikasexl cdk8noveltherapeuticopportunities |
| _version_ |
1724798579681263616 |